VIDEO: Patient-reported outcomes differ by age with anastrozole versus tamoxifen for DCIS

SAN ANTONIO – A highlight of this year’s San Antonio Breast Cancer Symposium was presentation of two large phase III trials comparing anastrozole to tamoxifen for prevention of recurrent disease in women with ductal carcinoma in situ.

In an interview, Dr. Patricia A. Ganz of the University of California, Los Angeles, breaks down the efficacy and quality of life differences between the two secondary prevention agents studied in NSABP B-35 and IBIS-II-DCIS.

[email protected]

SAN ANTONIO – A highlight of this year’s San Antonio Breast Cancer Symposium was presentation of two large phase III trials comparing anastrozole to tamoxifen for prevention of recurrent disease in women with ductal carcinoma in situ.

In an interview, Dr. Patricia A. Ganz of the University of California, Los Angeles, breaks down the efficacy and quality of life differences between the two secondary prevention agents studied in NSABP B-35 and IBIS-II-DCIS.

[email protected]

SAN ANTONIO – A highlight of this year’s San Antonio Breast Cancer Symposium was presentation of two large phase III trials comparing anastrozole to tamoxifen for prevention of recurrent disease in women with ductal carcinoma in situ.

In an interview, Dr. Patricia A. Ganz of the University of California, Los Angeles, breaks down the efficacy and quality of life differences between the two secondary prevention agents studied in NSABP B-35 and IBIS-II-DCIS.

[email protected]